CDSCO Tightens Action Against Banned Antibiotics After Shrimp Export Rejections Jump 43%

Date:

Share post:

The Central Drugs Standard Control Organisation (CDSCO), under India’s Ministry of Health and Family Welfare, has issued a directive to all State and Union Territory Drug Controllers mandating immediate reinforcement of surveillance measures against the unlawful use of Chloramphenicol and Nitrofurans in food-producing animal rearing systems.

Despite March 2025 prohibition under Notification S.O. 1158 — citing human health risks and the availability of safer alternatives — antibiotic residues continue to surface in India’s shrimp export consignments, triggering a 43% rejection rate in 2025 by the European Union, United States, and Japan.

According to MPEDA data flagged by CDSCO, over 40 farms spread across Andhra Pradesh (74%), Odisha (13%), West Bengal (8.7%), and Gujarat (4.3%) have been identified in connection with rejected consignments. This comes at a critical juncture: India recorded a landmark ₹73,890.46 crore ($8.46 billion) in seafood exports in FY26, with frozen shrimp alone contributing $5.62 billion.

CDSCO has directed state authorities to report inspection numbers, enforcement outcomes, and punitive actions against violators under the Drugs & Cosmetics Act, 1940, ensuring drug supply exclusively through licensed channels.

Written By: Sayan Das 

Graphics by: Pramit Hazra

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Biozenta Lifescience to Build ₹1,250 Crore Oncology Plant in Barabanki, UP

Biozenta Lifescience Pvt. Ltd., a global leader in oncology medicines, has announced plans to establish a state-of-the-art manufacturing facility in Barabanki, Uttar...

​Zydus Collaborates with ICMR to Address Sickle Cell Disease as Desidustat Enters Phase III

Zydus Lifesciences Limited, in collaboration with the Indian Council of Medical Research (ICMR), has announced the successful completion of...

VELMENI Secures FDA Nod for Advanced AI-Driven 3D Dental Imaging

Sunnyvale, California-based dental AI firm VELMENI announced on July 23, 2026, that the U.S. FDA has granted 510(k)...

Oriflame India Transfers Manufacturing Operations to Akums Subsidiary Pure & Cure

Oriflame India has signed an agreement to transfer its Indian manufacturing operations to Pure and Cure Healthcare, a wholly...